Who to call at Madrigal Pharmaceuticals, and when

Fundz watches for the moments Madrigal Pharmaceuticals starts buying, and tells you who to reach.

An alert the day Madrigal Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Madrigal Pharmaceuticals, from your own LinkedIn network

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Madrigal Pharmaceuticals Enters First Amendment to Agreement with Roche

Jan 30, 2026

Contract Type

licensing

ConshohockenBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

On January 29, 2026, Madrigal Pharmaceuticals, Inc. entered into the First Amendment to its Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. This Amendment grants Madrigal exclusive control over patent term adjustments and extensions for its drug candidate Rezdiffra

Company Information

Company

Madrigal Pharmaceuticals

Location

Conshohocken, Pennsylvania, United States

About

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). The Company is focused on entering its next phase of expansion and growth as it ramps up for the launch of resmetirom and continues to build a more fully integrated organization.